Tolerability Profile and Discontinuation Causes of Sacubitril/Valsartan Treatment in ‘Real-life’ Patients with Heart Failure and Reduced Ejection Fraction

Saved in:

Bibliographic Details
Main Authors:	M Rizzo, I Colomer-Asenjo, G Cabello-Molina, S Marín-López, M Sutil-Vega, C Roca-Guerrero, F Taibi-Hajjami, D García-Vega, M Panelo-Rubio, M Bonastre-Thio, A Martínez-Rubio
Format:	Article
Language:	English
Published:	Radcliffe Medical Media 2020-05-01
Series:	European Cardiology Review
Online Access:	https://www.ecrjournal.com/articleindex/ecr.2020.15.1.PO9
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prescription of Sacubitril/Valsartan in Patients with Heart Failure and Reduced Ejection Fraction Attending an Outpatient Heart Failure Clinic
by: M Rizzo, et al.
Published: (2020-05-01)

Baseline left ventricular ejection fraction predicts the magnitude of improvement in patients taking sacubitril/valsartan
by: José-Manuel Rubio-Campal, et al.
Published: (2025-06-01)

Efficacy of sacubitril/valsartan among patients with chronic heart failure with reduced ejection fraction
by: Madiha Butt, et al.
Published: (2024-09-01)

Experience of sacubitril/valsartan therapy in hypertension
by: E. V. Oshchepkova
Published: (2023-09-01)

Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end‐stage of renal disease
by: Seonhwa Lee, et al.
Published: (2020-06-01)

Potential of valsartan+sacubitril therapy in hypertensive heart disease
by: A. G. Ovchinnikov, et al.
Published: (2021-08-01)

Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)

Pathogenetic justification of sacubitril / valsartan use in respiratory-cardial comorbidity
by: T. V. Ashcheulova, et al.
Published: (2023-01-01)

The use of sacubitril/valsartan in different forms of heart failure
by: Mohammad Abumayyaleh, et al.
Published: (2025-06-01)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
by: Ying Ding, et al.
Published: (2023-12-01)

Expert Opinion on the Role of Sacubitril/Valsartan in the Management of Hypertension in India
by: Uday M. Jadhav, et al.
Published: (2024-11-01)

EFFECTS OF SACUBITRIL/VALSARTAN ON THE ARTERIAL STIFFNESS AND LEFT VENTRICULAR-ARTERIAL COUPLING IN PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION
by: Zh. D. Kobalava, et al.
Published: (2018-05-01)

Heart failure with reduced ejection fraction developed from valvular surgery: Risk factors and therapeutic effects of sacubitril valsartan
by: Chen Yuqian, et al.
Published: (2025-04-01)

Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM‐HF
by: Misato Chimura, et al.
Published: (2025-05-01)

Drug-Induced Acute Dystonia After Sacubitril/Valsartan Combination
by: Prabhat Tewari, et al.
Published: (2024-02-01)

In‐Hospital or Out‐of‐Hospital Initiation of Sacubitril/Valsartan Versus Valsartan in Patients With Mildly Reduced or Preserved Ejection Fraction After A Worsening Heart Failure Event: The PARAGLIDE‐HF Trial
by: Nina Nouhravesh, et al.
Published: (2025-03-01)

Characteristics, Predictors, and Clinical Outcomes in Heart Failure With Reduced Ejection Fraction According to a 1‐Year Left Ventricular Ejection Fraction Following Sacubitril/Valsartan Treatment
by: Chan Soon Park, et al.
Published: (2024-11-01)

The Effect of Sacubitril/Valsartan on Supraventricular and Ventricular Arrhythmias in Patients With Heart Failure
by: Alireza Arzhangzadeh, et al.
Published: (2025-05-01)

EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
by: Zh. D. Kobalava, et al.
Published: (2017-07-01)

Use of sacubitril/valsartan in non‐compaction cardiomyopathy: a case report
by: Marcely Gimenes Bonatto, et al.
Published: (2020-06-01)

Corrigendum: The concentration of maternal sacubitril/valsartan transferred into human milk is negligible
by: Sirin Falconi, et al.
Published: (2024-11-01)

Assessment of Left Ventricular Reverse Remodeling by Echocardiography After 90 Days of Sacubitril/Valsartan Therapy in Patients of Heart Failure with Reduced Ejection Fraction
by: Akshay Pawar, et al.
Published: (2024-12-01)

The in‐hospital administration of sacubitril/valsartan in acute myocardial infarction: A meta‐analysis
by: Gianluca Di Pietro, et al.
Published: (2025-04-01)

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats
by: Einar Sjaastad Nordén, et al.
Published: (2025-04-01)

Progress of sacubitril valsartan in researches on chronic kidney disease with diabetes and cardiovascular disease
by: YANG Hui-juan, et al.
Published: (2020-01-01)

Dosing patterns and dose effects of sacubitril/valsartan: A claims-based retrospective cohort study.
by: Jillian M Rung, et al.
Published: (2025-01-01)

Supramolecular complex sacubitril/valsartan - the first representative of a new class of drugs for the treatment of chronic heart failure
by: T. V. Ashcheulova, et al.
Published: (2019-12-01)

Effects of Sacubitril/Valsartan on Blood Pressure and Proteinuria in Hypertensive Patients With Chronic Kidney Disease
by: Maki Murakoshi, et al.
Published: (2025-07-01)

BOLD MRI to Evaluate the Effects of Sacubitril/Valsartan on Renal Protection in Type 2 Diabetics
by: Zhai L, et al.
Published: (2025-05-01)

Dose-dependent renoprotective effects of sacubitril/valsartan in heart failure: a retrospective study
by: Takahiro Kato, et al.
Published: (2025-12-01)

Initiating Empagliflozin and Sacubitril/Valsartan Early After Acute Myocardial Infarction: Mechanistic Study
by: Daina Martínez‐Falguera, et al.
Published: (2025-06-01)

Effectiveness of Sacubitril/Valsartan in Preventing Heart Failure in STEMI Post-Percutaneous Coronary Intervention
by: Nobian Andre, et al.
Published: (2023-12-01)

Effects of sacubitril/valsartan on hypertensive heart disease: the REVERSE-LVH randomized phase 2 trial
by: Vivian Lee, et al.
Published: (2025-07-01)

Effectiveness of neoton in patients with heart failure receiving sacubitril/valsartan. Sub-analysis of the BYHEART study
by: S. N. Tereshchenko, et al.
Published: (2024-06-01)

Sacubitril-Valsartan Lowers Blood Pressure in Patients on Dialysis: A Randomized Controlled Multicenter Study
by: Li Lin, et al.
Published: (2025-01-01)

Comparison of Metoprolol and Sacubitril/Valsartan in Chinese Patients With Heart Failure: A Retrospective Cohort Study
by: Yali Huang, et al.
Published: (2025-05-01)

Effect of sacubitril/valsartan on inflammation and oxidative stress in doxorubicin-induced heart failure model in rabbits
by: Yu Chun, et al.
Published: (2021-09-01)

Sacubitril/Valsartan attenuates progression of diabetic cardiomyopathy through immunomodulation properties: an opportunity to prevent progressive disease
by: Narainrit Karuna, et al.
Published: (2025-05-01)

Retrospective Analysis of Sacubitril/Valsartan vs Benazepril for Treating Heart Failure Following Acute Myocardial Infarction
by: Zhao L, et al.
Published: (2024-12-01)

Angiotensin Receptor–Neprilysin Inhibition (Sacubitril/Valsartan) Reduces Structural Arterial Stiffness in Middle‐Aged Mice
by: Isabel N. Schellinger, et al.
Published: (2024-02-01)